Athersys, Inc. Receives Orphan Drug Designation for MultiStem in Hurler's Syndrome

Full story: BioSpace
Athersys, Inc. announced today that MultiStemA , Athersys' proprietary cell therapy, has been granted orphan drug designation by the U.S. Food and Drug Administration for the treatment of Hurler's Syndrome, also known as mucopolysaccharidosis type I or MPS-I. Hurler's Syndrome is a lysosomal storage disorder that affects approximately 1 of every ... (more) Full Story
athxer

Singapore, Singapore

#1 Jul 11, 2012
any idea when a partnership for this is happening??? Don;t wish to see another dilution exercise.
athxer

Singapore, Singapore

#2 Jul 17, 2012
I'm starting to loose patience at Athersys. Whenever there's slightest bit of positive news, this damn stock will go down and remain down.

Tell me when this thread is updated:

Subscribe Now Add to my Tracker

Add your comments below

Characters left: 4000

Please note by submitting this form you acknowledge that you have read the Terms of Service and the comment you are posting is in compliance with such terms. Be polite. Inappropriate posts may be removed by the moderator. Send us your feedback.

Biotech Discussions

Title Updated Last By Comments
Eli Lilly's injectable diabetes drug OK'd 1 hr Dave 4
China fines British drug maker GlaxoSmithKline ... Fri RayH 1
CDC to board ship from Africa with sick crew Sep 17 Marine Phoenix 1
Ebola Poses a New Challenge for U.S. Military Sep 17 Gre 1
CDC Fears Ebola Virus 'Out of Control'; Human T... Sep 17 VirusCancerkiller 1
Girls have been urged to have the HPV jab Sep 15 A con is on 1
Teva Pharmaceutical Is Poised To Grow Sep 14 PA Pharmacist 1
•••

Biotech People Search

Addresses and phone numbers for FREE

•••